Literature DB >> 19590505

Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.

Narihisa Matsuyama1, Takeshi Tsutsumi, Nami Kubota, Toshiaki Nakajima, Hiroshi Suzuki, Youici Takeyama.   

Abstract

In this study, the inhibitory action of angiotensin II (Ang II) receptor blocker (ARB) on Ang II-induced conduction blocking in the left atrium was studied. Transmembrane action potentials and effective refractory period (ERP) were recorded from the left atrial trabeculae of spontaneously hypertensive rats (SHR(Izm)s) that had been treated with or without olmesartan medoxomil (AT1 receptor blocker, 3.0 mg kg(-1)) for 8 weeks before the recording. During rapid electrical stimulation (RES), changes in activation time (AT) and frequencies of the conduction block were studied under perfusion of Ang II (10(-8) M) or Ang II plus ARB (10(-7) M). Interstitial fibrosis in the left atrium was quantitatively assessed using histological sections. Although action potential parameters and ERP did not differ between the two groups when preparations were driven with a basic cycle length, an Ang II-induced conduction delay was observed during RES, and this was significantly suppressed in SHR(Izm)s treated with ARB (P<0.05). The Ang II-induced conduction block was also significantly reduced with perfusion of ARB (P<0.05). The interstitial fibrous area was significantly larger in untreated SHR(Izm)s than in treated animals (P<0.01). This antagonizing action of AT1 blockade might contribute to its non-antiarrhythmic therapeutic effect on atrial fibrillation because of its indirect and direct actions on the structural and functional remodeling of the left atrium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590505     DOI: 10.1038/hr.2009.89

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  10 in total

Review 1.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 2.  Atrial Fibrillation and Metabolic Syndrome: Understanding the Connection.

Authors:  Prabhat Kumar; Anil K Gehi
Journal:  J Atr Fibrillation       Date:  2012-10-06

3.  Association of interleukin 17 / angiotensin II with refractory hypertension risk in hemodialysis patients.

Authors:  Zebin Wang; Wei Shi; Xinling Liang; Wenjian Wang; Jianbo Liang
Journal:  Afr Health Sci       Date:  2016-09       Impact factor: 0.927

4.  Left ventricular extracellular volume fraction and atrioventricular interaction in hypertension.

Authors:  Jonathan C L Rodrigues; Tamas Erdei; Amardeep Ghosh Dastidar; Gergley Szantho; Amy E Burchell; Laura E K Ratcliffe; Emma C Hart; Angus K Nightingale; Julian F R Paton; Nathan E Manghat; Mark C K Hamilton
Journal:  Eur Radiol       Date:  2018-09-19       Impact factor: 5.315

5.  Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing.

Authors:  Dennis H Lau; Nicholas J Shipp; Darren J Kelly; Shivshankar Thanigaimani; Melissa Neo; Pawel Kuklik; Han S Lim; Yuan Zhang; Karen Drury; Christopher X Wong; Nicholas H Chia; Anthony G Brooks; Hany Dimitri; David A Saint; Lindsay Brown; Prashanthan Sanders
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  J Arrhythm       Date:  2016-07-11

7.  What Is the Ideal Blood Pressure Treatment Target for Primary Prevention and Management of Atrial Fibrillation?

Authors:  Xianghong Meng; Xiaoyong Xu
Journal:  Front Cardiovasc Med       Date:  2020-11-27

Review 8.  Hypertension and Arrhythmias: A Clinical Overview of the Pathophysiology-Driven Management of Cardiac Arrhythmias in Hypertensive Patients.

Authors:  Jacopo Marazzato; Federico Blasi; Michele Golino; Paolo Verdecchia; Fabio Angeli; Roberto De Ponti
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-06

Review 9.  Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment.

Authors:  Riccardo M Inciardi; Andrea Bonelli; Tor Biering-Sorensen; Matteo Cameli; Matteo Pagnesi; Carlo Mario Lombardi; Scott D Solomon; Marco Metra
Journal:  Eur J Heart Fail       Date:  2022-06-06       Impact factor: 17.349

10.  Effects of Acupuncture on Cardiac Remodeling in Patients with Persistent Atrial Fibrillation: Results of a Randomized, Placebo-Controlled, Patient- and Assessor-Blinded Pilot Trial and Its Implications for Future Research.

Authors:  Jung Myung Lee; Seung Min Kathy Lee; Jungtae Leem; Jin-Bae Kim; Jimin Park; Jun Hyeong Park; Suji Lee; Hyung Oh Kim; Hyemoon Chung; Jong Shin Woo; Woo-Shik Kim; Sanghoon Lee; Weon Kim
Journal:  Medicina (Kaunas)       Date:  2021-12-27       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.